MedPath

European Organisation For Research & Treatment Of Cancer

🇬🇧United Kingdom
Ownership
Private
Employees
-
Market Cap
-
Website
http://www.eortc.be

Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma

Phase 3
Terminated
Conditions
Intraocular Melanoma
Metastatic Cancer
First Posted Date
2005-05-04
Last Posted Date
2012-09-24
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
171
Registration Number
NCT00110123
Locations
🇮🇹

European Institute of Oncology, Milan, Italy

🇮🇹

Istituto Nazionale per lo Studio e la Cura dei Tumori, Naples, Italy

🇮🇹

Azienda Ospedaliera di Padova, Padova, Italy

and more 5 locations

Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant

Phase 2
Completed
Conditions
Cancer
First Posted Date
2005-05-04
Last Posted Date
2012-09-24
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
171
Registration Number
NCT00110045
Locations
🇸🇰

National Cancer Institute - Bratislava, Bratislava, Slovakia

🇨🇭

Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

🇩🇪

Medizinische Poliklinik, Universitaet Wuerzburg, Wuerzburg, Germany

and more 10 locations

Radiotherapy or Radiosurgery Compared With Observation Alone in Treating Patients With Newly Diagnosed, Benign Meningioma That Has Been Partially Removed by Surgery

Phase 3
Terminated
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2005-03-04
Last Posted Date
2012-09-24
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
9
Registration Number
NCT00104936
Locations
🇳🇱

Radiotherapeutisch Instituut-(Riso), Deventer, Netherlands

🇨🇭

Hopital Cantonal Universitaire de Geneve, Geneva, Switzerland

🇩🇪

University Hospital Schleswig-Holstein - Kiel Campus, Kiel, Germany

and more 1 locations

Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor

Phase 3
Completed
Conditions
Gastrointestinal Stromal Tumor
Interventions
First Posted Date
2005-02-08
Last Posted Date
2018-07-09
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
908
Registration Number
NCT00103168
Locations
🇬🇧

Christie Hospital, Manchester, England, United Kingdom

🇬🇧

Gartnavel General Hospital, Glasgow, Scotland, United Kingdom

🇫🇷

Hopital Avicenne, Bobigny, France

and more 47 locations

Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer

Phase 2
Completed
Conditions
Lung Cancer
First Posted Date
2005-02-08
Last Posted Date
2012-07-16
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Registration Number
NCT00103051
Locations
🇳🇱

Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer

Phase 1
Completed
Conditions
Colorectal Cancer
First Posted Date
2004-12-09
Last Posted Date
2013-06-12
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
16
Registration Number
NCT00098982
Locations
🇨🇭

Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

🇬🇧

Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom

🇮🇹

Istituto Nazionale per lo Studio e la Cura dei Tumori, Naples, Italy

NGR-TNF in Treating Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Colorectal Cancer
Head and Neck Cancer
Kidney Cancer
Unspecified Adult Solid Tumor, Protocol Specific
First Posted Date
2004-12-09
Last Posted Date
2012-09-24
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
70
Registration Number
NCT00098943
Locations
🇳🇱

Universitair Medisch Centrum St. Radboud - Nijmegen, Nijmegen, Netherlands

🇩🇪

University Medical Center Hamburg - Eppendorf, Hamburg, Germany

Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Phase 2
Conditions
Leukemia
First Posted Date
2004-09-09
Last Posted Date
2012-07-24
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
279
Registration Number
NCT00091234
Locations
🇮🇹

Ospedale Binaghi, Cagliari, Italy

🇮🇹

Ospedale Oncologico A. Businco, Cagliari, Italy

🇮🇹

Ospedale Di Montefiascone, Montefiascone, Italy

and more 42 locations

Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 3
Terminated
Conditions
Lung Cancer
First Posted Date
2004-09-08
Last Posted Date
2012-07-16
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
598
Registration Number
NCT00091156
Locations
🇧🇪

Clinique Sainte Elisabeth, Namur, Belgium

🇨🇾

Bank Of Cyprus Oncology Centre, Nicosia, Cyprus

🇪🇬

National Cancer Institute of Egypt, Cairo, Egypt

and more 25 locations

Ecteinascidin 743 in Treating Adults With Advanced Solid Tumors

Phase 1
Completed
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
First Posted Date
2004-09-03
Last Posted Date
2012-07-02
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
40
Registration Number
NCT00002904
Locations
🇫🇷

Centre Oscar Lambret, Lille, France

🇩🇪

Martin Luther Universitaet, Halle Saale, Germany

🇩🇪

Universitats-Krankenhaus Eppendorf, Hamburg, Germany

and more 46 locations
© Copyright 2025. All Rights Reserved by MedPath